Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Comparable Efficacy ◽

Line Treatment

Phase II Study of Single-Agent Pegylated Liposomal Doxorubicin HCl (PLD) in Metastatic Breast Cancer After First-Line Treatment Failure

Oncology Research and Treatment ◽

10.1159/000080363 ◽

2004 ◽

Vol 27 (5) ◽

pp. 441-446 ◽

Cited By ~ 7

Author(s):

B. Mlineritsch ◽

P. Mayer ◽

C. Rass ◽

E. Reiter ◽

G. Russ ◽

...

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Single Agent ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Non-pegylated liposomal doxorubicin and docetaxel as first-line treatment in metastatic breast cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.753 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 753-753 ◽

Cited By ~ 3

Author(s):

V. Heilmann ◽

H. Eggemann ◽

H. Sommer ◽

G. Heinrich ◽

J.-U. Blohmer ◽

...

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Pegylated Liposomal Doxorubicin (Doxil®) Versus Doxorubicin for First-Line Treatment of Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/s1526-8209(11)70179-3 ◽

2002 ◽

Vol 3 (3) ◽

pp. 183-184 ◽

Cited By ~ 3

Author(s):

Kavita Maung ◽

Joyce O'Shaughnessy ◽

Beth Overmoyer

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Phase I-II Study of Pegylated Liposomal Doxorubicin Combined With Weekly Paclitaxel as First-Line Treatment in Patients With Metastatic Breast Cancer

American Journal of Clinical Oncology ◽

10.1097/01.coc.0000217552.69036.16 ◽

2006 ◽

Vol 29 (3) ◽

pp. 267-275 ◽

Cited By ~ 9

Author(s):

Hugues Bourgeois ◽

Aur??lie Ferru ◽

Alain Lortholary ◽

Thierry Delozier ◽

Mich??le Boisdron-Celle ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

Line Treatment ◽

First Line ◽

Non Pegylated Liposomal Doxorubicin Beyond the First Line Treatment of Metastatic Breast Cancer Patients: A Retrospective Analysis

Annals of Oncology ◽

10.1016/s0923-7534(20)32919-7 ◽

2012 ◽

Vol 23 ◽

pp. ix128-ix129

Author(s):

S. Bernhard ◽

L. Mansi ◽

V. Nerich ◽

C.B. Villanueva ◽

E. Dobi ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Line Treatment ◽

Breast Cancer Patients ◽

First Line ◽

Weekly paclitaxel (T) and pegylated liposomal doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patient

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.704 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 704-704 ◽

Cited By ~ 4

Author(s):

F. Fulfaro ◽

M. R. Valerio ◽

G. Badalamenti ◽

C. Arcara ◽

G. Cicero ◽

...

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

Line Treatment ◽

First Line ◽

Weekly paclitaxel (T) and pegylated liposomal doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patient

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.704 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 704-704

Author(s):

F. Fulfaro ◽

M. R. Valerio ◽

G. Badalamenti ◽

C. Arcara ◽

G. Cicero ◽

...

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

Line Treatment ◽

First Line ◽

Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis

Anti-Cancer Drugs ◽

10.1097/00001813-200606000-00014 ◽

2006 ◽

Vol 17 (5) ◽

pp. 587-595 ◽

Cited By ~ 60

Author(s):

Gerald Batist ◽

Lyndsay Harris ◽

Nozar Azarnia ◽

Lily Waiyee Lee ◽

Pascual Daza-Ramirez

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Tumor Response ◽

Response Rate ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer

Oncology Research and Treatment ◽

10.1159/000180915 ◽

2009 ◽

Vol 32 (1-2) ◽

pp. 18-24 ◽

Cited By ~ 7

Author(s):

Brigitte Mlineritsch ◽

Renate Schabel-Moser ◽

Johannes Andel ◽

Michael Fridrik ◽

Martin Moik ◽

...

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer

European Journal of Cancer ◽

10.1016/j.ejca.2011.05.005 ◽

2011 ◽

Vol 47 (14) ◽

pp. 2091-2098 ◽

Cited By ~ 16

Author(s):

D. Amadori ◽

C. Milandri ◽

G. Comella ◽

S. Saracchini ◽

S. Salvagni ◽

...

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Locally Advanced ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her 2 ◽